Brian A. Whiteman

Array ( [id] => 18666512 [patent_doc_number] => 11773390 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNA [patent_app_type] => utility [patent_app_number] => 17/125245 [patent_app_country] => US [patent_app_date] => 2020-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 145788 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17125245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451999 [patent_doc_number] => 20230193278 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => MULTI-TARGETED siRNA FOR TREATING CANCERS [patent_app_type] => utility [patent_app_number] => 17/798236 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17798236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885753 [patent_doc_number] => 20210171948 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => COMPOSITIONS AND METHODS FOR TARGETING GLYPICAN-2 IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/116214 [patent_app_country] => US [patent_app_date] => 2020-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17116214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18251161 [patent_doc_number] => 20230078200 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION [patent_app_type] => utility [patent_app_number] => 17/783232 [patent_app_country] => US [patent_app_date] => 2020-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28143 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17783232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17370311 [patent_doc_number] => 20220025363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES [patent_app_type] => utility [patent_app_number] => 17/115791 [patent_app_country] => US [patent_app_date] => 2020-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 96860 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17115791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17037108 [patent_doc_number] => 20210254066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => Nucleic Acid Molecules and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/247265 [patent_app_country] => US [patent_app_date] => 2020-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11401 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17247265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18126404 [patent_doc_number] => 20230012024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => METHODS FOR CONTROLLING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) COAGULATION [patent_app_type] => utility [patent_app_number] => 17/782848 [patent_app_country] => US [patent_app_date] => 2020-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511645 [patent_doc_number] => 20230227820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => RNA INTERFERENCE-INDUCING NUCLEIC ACID COMPRISING 8-OXOGUANINE, MODIFIED NUCLEIC ACID BINDING TO MICRORNA COMPRISING 8-OXOGUANINE, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/780600 [patent_app_country] => US [patent_app_date] => 2020-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091311 [patent_doc_number] => 20220409652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => miRNA-BASED PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND THE TREATMENT OF TISSUE DISORDERS [patent_app_type] => utility [patent_app_number] => 17/781150 [patent_app_country] => US [patent_app_date] => 2020-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30147 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17781150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497707 [patent_doc_number] => 20230220385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => MICRORNA AS A THERAPEUTIC AGENT [patent_app_type] => utility [patent_app_number] => 17/779293 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883723 [patent_doc_number] => 20210169918 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY [patent_app_type] => utility [patent_app_number] => 16/949980 [patent_app_country] => US [patent_app_date] => 2020-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16949980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839830 [patent_doc_number] => 20210147842 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => METHODS AND COMPOSITIONS FOR INHIBITING NECROPTOSIS IN NEUROVASCULAR AND/OR NEURODEGENERATIVE DISEASES OR DISORDERS [patent_app_type] => utility [patent_app_number] => 17/097695 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17097695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16976037 [patent_doc_number] => 20210220274 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY [patent_app_type] => utility [patent_app_number] => 17/094724 [patent_app_country] => US [patent_app_date] => 2020-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44303 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17094724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18109886 [patent_doc_number] => 20230002766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING BROMODOMAIN CONTAINING PROTEIN 4 (BRD4) FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/775148 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16808275 [patent_doc_number] => 20210130828 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => GIN RECOMBINASE VARIANTS [patent_app_type] => utility [patent_app_number] => 17/085319 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17085319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19156167 [patent_doc_number] => 20240148874 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => IMMUNOADJUVANT-BASED HYDROGEL COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/044565 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16793240 [patent_doc_number] => 20210123057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => Sequence Multiplicity Within Spherical Nucleic Acids [patent_app_type] => utility [patent_app_number] => 17/084460 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17084460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18181764 [patent_doc_number] => 20230042493 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => CTGF GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE, AND A COMPOSITION FOR PREVENTING AND TREATING FIBROTIC DISEASES AND RESPIRATORY-RELATED DISEASES COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 17/778836 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14945 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762631 [patent_doc_number] => 20210108212 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => RNAi Constructs for Inhibiting ASGR1 Expression and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 17/080771 [patent_app_country] => US [patent_app_date] => 2020-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17080771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612198 [patent_doc_number] => 20210030851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY [patent_app_type] => utility [patent_app_number] => 17/072056 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7678 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072056 [rel_patent_id] =>[rel_patent_doc_number] =>)